Physician profile
Jennifer Miley
NPI 1154338424
$7,011.59
in general payments reported to CMS, 2019-2025
51 companies · $980 in 2025
The $980 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $677 · 2021: $827 · 2022: $952 · 2023: $1,469 · 2024: $1,433 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,666 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,666.39 |
| Education | $215.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.07 | 2021-2025 | |
| Pfizer INC. | $654.63 | 2019-2025 | |
| Amgen INC. | $451.08 | 2019-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $441.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $417.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $351.79 | 2019-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $335.27 | 2019-2025 | Spravato, Xarelto |
| Astellas Pharma US INC | $332.70 | 2019-2025 | Veozah |
| Abbott Laboratories | $313.29 | 2020-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $265.55 | 2020-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.33 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $188.03 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $174.09 | 2024 | Qelbree |
| Lundbeck LLC | $156.76 | 2021-2024 | Rexulti, Vyepti |
| Radius Health, INC. | $145.90 | 2019-2025 | Tymlos |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Miley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.